EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtÜbersichtsarbeitOpen Access · CC BY 4.0

Meta‐Analysis: Safety and Effectiveness of Advanced Therapies in Inflammatory Bowel Disease Patients With Concomitant Primary Sclerosing Cholangitis

Amera Elzubeir iD, Anjana Kumar iD, Alistair McArdle iD, Emily Holden, Leo Alexandre, Simon Rushbrook iD, Kate D Lynch iD

Alimentary Pharmacology & Therapeutics · 2026

DOI: 10.1111/apt.71045 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2026. Verfasst von Amera Elzubeir und 6 weiteren Autor:innen. Beteiligte Einrichtung: Norwich Medical School, University of East Anglia, Norwich, UK. Hauptthemen laut MEDLINE: Cholangitis, Sclerosing, Inflammatory Bowel Diseases, Gastrointestinal Agents. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Inflammatory bowel disease (IBD) associated with primary sclerosing cholangitis (PSC) is a distinct phenotype (PSC‐IBD). Data on the safety and effectiveness of advanced IBD therapies on IBD outcomes in PSC‐IBD remain limited.

Methods

A systematic review and meta‐analysis assessed the safety and effectiveness of advanced therapies in adults with PSC‐IBD. MEDLINE, Embase, Cochrane databases and Web of Science were searched to July 2026. The primary outcome was IBD clinical remission. Secondary outcomes included clinical response, corticosteroid‐free remission, mucosal healing, adverse event‐related treatment discontinuation and colorectal neoplasia. A random‐effects model was used for pooled estimates.

Results

Five retrospective case‐series ( n = 394) evaluating infliximab, adalimumab, vedolizumab and tofacitinib were included (median follow‐up of 18.4 months). Pooled clinical remission rates were 24.7% (95% CI: 17.2%–33.0%) at 3 months and 28.6% (95% CI: 16.3%–42.6%) at 6–12 months. Corticosteroid‐free remission was achieved in 45.4% (95% CI: 33.1%–57.9%) and mucosal healing in 25.6% (95% CI: 13.6%–39.5%). Tofacitinib was associated with a clinical response rate of 59.3% (95% CI: 40.0%–77.2%) and low adverse event rate, in a single available study. Adverse event‐related discontinuation occurred in 9.1% (95% CI: 4.4%–15.1%), while 31.8% (95% CI: 25.5%–38.5%) experienced primary non‐response or secondary loss of response. The pooled proportion of colorectal neoplasia was 10.5% (12/112; 95% CI: 5.3%–17.1%). Five patients developed colorectal cancer (5/112; 4.3%) and two (2/177; 0.8%) cholangiocarcinoma.

Conclusion

Advanced IBD therapies demonstrate modest but encouraging effectiveness and an acceptable safety profile in PSC‐IBD; however, the available evidence is limited by retrospective study designs, small sample sizes and substantial clinical and methodological heterogeneity. Prospective controlled studies using standardised IBD outcomes are needed to inform optimal therapeutic strategies in this high‐risk population. Trial Registration PROSPERO: CRD42024580296

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholangitis, SclerosingInflammatory Bowel DiseasesGastrointestinal AgentsHumansTreatment OutcomeAntibodies, Monoclonal, HumanizedInfliximabRemission InductionPyrimidinesAdultAdalimumabPiperidines

Stichwörter der Autor:innen

Crohn's diseaseadvanced therapieseffectivenessefficacyinflammatory bowel diseaseprimary sclerosing cholangitisprimary sclerosing cholangitis associated inflammatory bowel diseasesafetyulcerative colitis

Substanzen

Antibodies, Monoclonal, HumanizedGastrointestinal AgentsInfliximabtofacitinibPyrimidinesAdalimumabPiperidinesvedolizumab

Autor:innen und Institutionen

  • Norwich Medical School, University of East Anglia, Norwich, UK.
  • Department of Gastroenterology, Norfolk and Norwich University Hospital NHS Foundation Trust, Norwich, UK.
  • Department of General Surgery, Norfolk and Norwich University Hospital NHS Foundation Trust, Norwich, UK.
  • Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, Australia.
  • College of Health, Adelaide University, Adelaide, Australia.

ORCID-Profile: Amera Elzubeir, Anjana Kumar, Alistair McArdle, Simon Rushbrook, Kate D Lynch

Förderung

  • National Institute for Health and Care Research

Zitieren

APA

Elzubeir, A., Kumar, A., McArdle, A., Holden, E., Alexandre, L., Rushbrook, S., & Lynch, K. D. (2026). Meta‐Analysis: Safety and Effectiveness of Advanced Therapies in Inflammatory Bowel Disease Patients With Concomitant Primary Sclerosing Cholangitis. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.71045

Vancouver

Elzubeir A, Kumar A, McArdle A, Holden E, Alexandre L, Rushbrook S, et al. Meta‐Analysis: Safety and Effectiveness of Advanced Therapies in Inflammatory Bowel Disease Patients With Concomitant Primary Sclerosing Cholangitis. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.71045

BibTeX
@article{Elzubeir2026,
  author = {Elzubeir, Amera and Kumar, Anjana and McArdle, Alistair and Holden, Emily and Alexandre, Leo and Rushbrook, Simon and Lynch, Kate D},
  title = {Meta‐Analysis: Safety and Effectiveness of Advanced Therapies in Inflammatory Bowel Disease Patients With Concomitant Primary Sclerosing Cholangitis},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1111/apt.71045}
}
Kostenlos starten →